The lastest infromation from shows that elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), is being investigated as a potential treatment for advanced breast cancer, specifically in patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative metastatic breast cancer. Here are some insights on the use of elacestrant in previously-treated, HER2-negative metastatic breast cancer:
Elacestrant has been evaluated in clinical trials to assess its safety and efficacy in patients with advanced breast cancer who have received prior hormonal therapies. These trials typically include patients whose disease has progressed on standard endocrine therapies like tamoxifen or aromatase inhibitors.
As a SERD, elacestrant works by blocking the estrogen receptor and inducing its degradation. Estrogen receptors play a crucial role in the growth and proliferation of hormone receptor-positive breast cancer cells. By targeting and degrading these receptors, elacestrant aims to inhibit tumor growth and potentially overcome resistance to other hormonal therapies.
Clinical trial data on the efficacy of elacestrant in previously-treated, HER2- metastatic breast cancer were promising. Results have shown that it achieved meaningful clinical responses in some patients who had developed resistance to previous hormonal therapies. However, it's essential to note that the effectiveness of elacestrant can vary from one patient to another.
As with any drug, elacestrant may cause side effects. Common side effects observed in clinical trials included fatigue, nausea, and hot flashes. However, the overall safety profile appeared manageable. The specific side effects and their severity may vary depending on individual patient characteristics and other factors.
As of the last update, elacestrant was still in the clinical trial phase, and further research was required to establish its long-term efficacy and safety. Regulatory approval and availability for commercial use would depend on the successful completion of clinical trials and approval by health authorities.